Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Other Events
Item 8.01 Other Events.

On March 14, 2017, Synergy Pharmaceuticals Inc. (the “Company”) issued a press release announcing that Marino Garcia, the Company’s EVP and Chief Strategy Officer, will present a corporate update at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 11:30 a.m. Eastern Time at The Westin New York Grand Central in New York City).

The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Synergy Pharmaceuticals Inc. Press Release dated March 14, 2017.

About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Recent Trading Information

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) closed its last trading session down -0.04 at 5.25 with 4,139,854 shares trading hands.